Cargando…
Impact of Laboratory-Adapted Intracellular Trypanosoma cruzi Strains on the Activity Profiles of Compounds with Anti-T. cruzi Activity
Chagas disease is caused by infection with the protozoan parasite, Trypanosoma cruzi. The disease causes ~12,000 deaths annually and is one of the world’s 20 neglected tropical diseases, as defined by the World Health Organisation. The drug discovery pipeline for Chagas disease currently has few new...
Autores principales: | Sykes, Melissa L., Kennedy, Emily K., Avery, Vicky M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967867/ https://www.ncbi.nlm.nih.gov/pubmed/36838441 http://dx.doi.org/10.3390/microorganisms11020476 |
Ejemplares similares
-
Temporal and Wash-Out Studies Identify Medicines for Malaria Venture Pathogen Box Compounds with Fast-Acting Activity against Both Trypanosoma cruzi and Trypanosoma brucei
por: Sykes, Melissa L., et al.
Publicado: (2022) -
Investigation of pyrimidine nucleoside analogues as chemical probes to assess compound effects on the proliferation of Trypanosoma cruzi intracellular parasites
por: Sykes, Melissa Louise, et al.
Publicado: (2020) -
Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes
por: Sykes, Melissa L., et al.
Publicado: (2015) -
Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds
por: Martinez-Peinado, Nieves, et al.
Publicado: (2021) -
3-pyridyl inhibitors with novel activity against Trypanosoma cruzi reveal in vitro profiles can aid prediction of putative cytochrome P450 inhibition
por: Sykes, Melissa L., et al.
Publicado: (2018)